However, the treatment landscape of CKD and T2D is evolving rapidly with the introduction of new agents such as sodium–glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide 1 receptor agonists (GLP-1 RAs), and finerenone. The gene discussed is GLP1R; the disease is chronic kidney disease.